GEM–IB

• Description :

  GEM–IB is the conjugate of gemcitabine (GEM) -5'-phosphate with ibandronate (IB) . GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) [1].

• UNSPSC :

  12352005

• Target :

  Drug Derivative

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/gem-ib.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCCCCN(CCC(P(O)(O)=O)(P(O)(OP(O)(OC[C@H]1O[C@H](C(F)([C@@H]1O)F)N2C=CC(N)=NC2=O)=O)=O)O)C

• Molecular Formula :

  C18H33F2N4O13P3

• Molecular Weight :

  644.39

• References & Citations :

  [1]Farrell KB, et al. Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel. Bioconjug Chem.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2866211-93-8]